Form 8K Tempest Therapeutics Inc For: 14 May
- Investing.com
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Tempest Therapeutics Inc (TPST)
The Tempest Therapeutics share price today is 1.8600, view NASDAQ TPST stock exchange data. Track the latest Tempest Therapeutics share price with real-time updates on TPST stock performance including market cap, day range, 52-week range and dividend yield. Access TPST charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.7400
1.8900
52 wk Range
1.5000
12.2300
TPST is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.74001.8900
52 wk Range
1.500012.2300
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
TPST Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
11.0000
Upside
+491.40%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
- Form 8K Tempest Therapeutics Inc For: 6 May
- Investing.com
- Form 13D/A Tempest Therapeutics For: 2 April
- Investing.com
- Form 8K Tempest Therapeutics Inc For: 14 May
- Investing.com
- Form 8K Tempest Therapeutics Inc For: 6 May
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Strong Buy
Moving Averages
Neutral
Analyst Ratings
1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 11.0000
(+491.40% Upside)
Earnings
Latest Release
14-05-2026
EPS / Forecast
-2.53 / -0.48
Revenue / Forecast
-- / --
Compare TPST to Peers and Sector
Metrics to compare | TPST | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTPSTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.6x | −3.2x | −0.5x | |
PEG Ratio | −0.01 | −0.01 | 0.00 | |
Price/Book | 32.5x | 2.6x | 2.6x | |
Price / LTM Sales | - | 120.4x | 3.1x | |
Upside (Analyst Target) | - | 95.7% | 54.0% | |
Fair Value Upside | Unlock | −9.7% | 6.5% | Unlock |
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Tempest Therapeutics (TPST) Share Price Today?
The Tempest Therapeutics share price today is 1.8600.
What is the current Tempest Therapeutics (TPST) share price and day range?
As of 21-05-2026, the Tempest Therapeutics share price is 1.8600, with a previous close of 1.8600. The share price has ranged from 1.7400 to 1.8900 today, while the 52-week range spans from 1.5000 to 12.2300.
What Is the Tempest Therapeutics Market Cap?
As of today, Tempest Therapeutics market cap is 26.6800M.
What Is the Tempest Therapeutics (TPST) Share Price Target?
The average 12-month share price target for Tempest Therapeutics is 11.0000, with a high estimate of 11 and a low estimate of 11. 1 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +491.40% Upside potential.
What Is Tempest Therapeutics's Earnings Per Share (TTM)?
The Tempest Therapeutics EPS (TTM) is -7.1553.
From a Technical Analysis Perspective, Is TPST a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Tempest Therapeutics Trade On?
Tempest Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Tempest Therapeutics?
The stock symbol for Tempest Therapeutics is "TPST."
How Many Times Has Tempest Therapeutics Stock Split?
Tempest Therapeutics has split 3 times.
How Many Employees Does Tempest Therapeutics Have?
Tempest Therapeutics has 4 employees.
What Is the TPST After Hours Price?
TPST's last after hours stock price is 1.8003, the stock has changed by -0.0597, or -3.2100%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.